“If I put myself on the list [for a kidney transplant] and just wait, that’s not proactive,” Okun said. “You get on the list and then do nothing, you might get a kidney and you might not get a kidney. And it’s [a wait of] anywhere from five to nine years.”

Quick Read

There are two medications that prevent preterm birth, the most common cause of perinatal death in the U.S. One costs 16 cents a week, one US$285. Poor black women aren’t getting either. Why?

Quick Read

Tasia Smith: “Politicians and scholars sometimes cast obesity as a problem that largely afflicts the poor. But as most obese adults aren’t poor and most low-income adults aren’t obese, this is a misconception”

Quick Read

The US is sitting on one of the largest data sets on any animal group, but most of it is inaccessible and restricted to local agencies

Quick Read

When doctors talk about a new leukemia drug from Novartis, they ooze enthusiasm, using words like “breakthrough,” “revolutionary” and “a watershed moment.” But when they think about how much the therapy is likely to cost, their tone turns alarmist. “It’s going to cost a fortune,” said Dr. Ivan Borrello at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore

Quick Read

And sees firsthand how hard it is. Galvanized by his teenage son’s epilepsy diagnosis, Mayes started a new company to try to shepherd a promising inhaler technology for epilepsy through a key clinical trial

Quick Read

If you watched the drama in Washington last month, you may have come away with the impression that the American health care system is a hopeless mess. So it is surprising that across the continent from Washington, investors and technology entrepreneurs in Silicon Valley see the American health care system as the next great market for reform

Quick Read

A new paper in the latest issue of Health Affairs is worth a look. “Drugs Cleared Through The FDA’s Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process“

Quick Read